Fri, Sep 19, 2014, 6:48 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Simulations Plus, Inc. Message Board

dickmilde 12 posts  |  Last Activity: Sep 10, 2014 8:28 AM Member since: Jan 2, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    SLP is getting bigger.

    by dickmilde Sep 4, 2014 7:55 PM
    dickmilde dickmilde Sep 10, 2014 8:28 AM Flag

    The share price is very volatile and nearly impossible to predict over the short term. For a longer time frame... say a year or more... I am expecting higher prices. This is because I expect management to continue to grow the company. The recent acquisition gives us a larger company at a fraction of the value of the prior SLP valuation. I'm confident that management will turn this into a measurable positive outcome for SLP and that the results will be reflected by a higher share price. The PE may come down some but the overall growth will continue and shareholders should be rewarded with a higher share price.

  • Just released FY2014 sales are about $11.3 Million... Up 11.9%... 4th quarter was up even more. Going forward we will see the Gognigen sales as well so we can expect around $16+ Million for the next year. Good job SLP... A big THANK YOU to Walt and the entire staff.

  • Reply to

    Yes... There will be some dilution.

    by dickmilde Jul 24, 2014 4:47 PM
    dickmilde dickmilde Jul 30, 2014 7:45 AM Flag

    The surviving subsidiary is the "new" Cognigen that is created for the purpose of the merger. The "new" Cognigen is the entity that is created for merging into SLP and survives the "old" Cognigen... But, SLP will remain the parent company with Cognigen as a subsidiary of SLP. It sounds confusing but it's just a paperwork deal for the purpose of the transaction.

  • Maintaining Speculative Buy rating. Our rating is
    based on new contracts with two top-five pharmaceutical
    companies, expanded simulation software sales to
    consumer product companies (that manufacture products
    such as detergent, makeup, toothpaste, etc.) that need
    toxicology capability, the launch of MembranePlus
    software in August 2014, modest price increases
    beginning in the 2H14, and a March 2014 distributor
    agreement signed with the Research Institute for Liver
    Diseases in Shanghai, China.
    We forecast income growth accelerating from 5.7% in FY14 to 32.8% in FY15

  • Reply to

    Yes... There will be some dilution.

    by dickmilde Jul 24, 2014 4:47 PM
    dickmilde dickmilde Jul 25, 2014 7:04 AM Flag

    There has been an additional press release with the following...
    "As noted in the initial press release, Cognigen is a profitable company and the Company anticipates it will continue to operate profitably. Because Cognigen’s revenues come primarily from consulting activities, the margins are not as high as for Simulations Plus’ software offerings, but management anticipates net margins of approximately 10 percent going forward,"

  • But you need to see this in the proper context... Walt is effectively buying $5 Million in sales which is about 1/2 the current sales for SLP. But, it's only costing us $7 Million to get those sales. Or another way to look at this is that he is getting a 50% sales increase and only using about 8% of the SLP market cap to get it. And to Jbailey's point SLP is the surviving company NOT Gogingen.
    There will be some challenges with this. Cogingen is located in New York and SLP is located in California. Walt is not a stranger to business travel so this should be OK, never the less I like close better because it's easier to keep an eye on things. Another point worth mentioning is that Cogingen has about 35 employees compared to SLP's 30 employees. I expect that over time that we will see a higher sales per employee ratio. This will probably come from increased sales for the same number of employees. Walt has a long time habit of finding productive stuff for employees to be involved in :-)

    As a summary I see an increase in total profit but a slight decline in profit margins... This will be corrected over time.

  • Simulations Plus, Inc. (SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that it has entered into an Agreement and Plan of Merger (the “Agreement”) with Cognigen Corporation of Buffalo, New York.

    Pursuant to the Agreement, upon closing, Cognigen will become a wholly-owned subsidiary of Simulations Plus and will continue to operate under the Cognigen name. This will result in the total number of Simulations Plus employees increasing from 30 to 65, and is expected to add approximately $5 million to the revenues of the combined company in the coming fiscal year.
    Walt Woltosz, chairman and chief executive officer of Simulations Plus, Inc., said, “This is an exciting step forward for both Simulations Plus and Cognigen. Upon closing, management of the combined company will be comprised of individuals from the current management teams of Simulations Plus and Cognigen, including Ted Grasela, the current President of Cognigen. I will remain as Chairman and CEO.”
    Under the terms of the Agreement, Simulations Plus will pay the shareholders of Cognigen total consideration of $7,000,000, comprised of $2,800,000 of cash and $4,200,000 worth of newly-issued, unregistered shares of common stock of Simulations Plus.

  • If you missed it there is a replay available on the SLP website. Click on "Investors" and select conference calls. From the sound of it the aerodynamic modeling was well received in Huntsville. This is a new and exciting area that has possibilities for additional revenue. It looks like our little company will be larger next year with increased sales :-)

  • Simulations Plus Reports Third Quarter FY2014 Financial Results
    Simulations Plus, Inc. (SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its third quarter of fiscal year 2014 ended May 31, 2014 (3QFY14) and first nine months of fiscal year 2014 (9moFY14) compared to the third quarter (3QFY13) and first nine months of fiscal year 2013 (9moFY13).

    3QFY14 highlights compared with 3QFY13:
    • Net sales increased 20.9% to $3.741 million, an increase of $646,000 from $3.095 million • A large renewal order and one study contract slipped from Q2 into Q3 ($300,000)
    • Excluding this shift, the Company set a new record for revenues (11.2% increase)

    • Gross profit was up 32.9% to $3.513 million, an increase of $870,000 from $2.643 million
    • SG&A was $1.204 million, an increase of 33.3% or $301,000 from $0.904 million • Increased commissions on higher Asian sales, as well as increased marketing labor and travel, consulting and professional fees, and increases in salaries and wages, drove the increased SG&A

    • R&D expenditures were $552,000, an increase of $94,000 or 20.5% over $458,000 • In 3QFY14, $317,000 was capitalized and $235,000 was expensed
    • In 3QFY13, $252,000 was capitalized and $206,000 was expensed
    • Increases were due to expanded staff, and increases in salaries and stock-based compensation for existing employees

    • Income before taxes increased 35.2% to $2.089 million, an increase of $544,000 from $1.546 million
    • Net income increased 31.6% to $1.307 million , an increase of $314,000 from $993,000
    • Diluted earnings per share increased 30.7% to $0.079 from $0.061

  • John DiBella, vice president of marketing and sales for Simulations Plus, said: “We’re very pleased that the U.S. Environmental Protection Agency has decided to expand their Simulations Plus software licenses by adding multiple licenses of our industry-leading GastroPlus™ and ADMET Predictor™ software packages. Researchers in different divisions at the agency have appreciated how our programs communicate with each other, allowing them to efficiently screen compounds and prioritize testing for several scientific initiatives.

  • Reply to

    Walt- How about supporting the price?

    by kauiakid Jun 20, 2014 1:20 PM
    dickmilde dickmilde Jun 25, 2014 6:40 AM Flag

    Maybe you can save us the time to look this up... Can you give us a link re the details of when and how much stock they said they would buy? Also, it would be helpful if you give us the info on hoe much they actually bought. Thanks.

  • Reply to

    Walt- How about supporting the price?

    by kauiakid Jun 20, 2014 1:20 PM
    dickmilde dickmilde Jun 23, 2014 4:03 PM Flag

    And what percent of the total stock do you think he should own ?

7.000.00(0.00%)Sep 19 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.